{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:22:49Z","timestamp":1790655769322,"version":"4.1.0"},"reference-count":64,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Individual resistance to cholera infection and disease depends on both innate host factors and adaptive immunity acquired by a previous infection or vaccination. Locally produced, intestinal-mucosal secretory IgA (SIgA) antibodies against bacterial surface lipopolysaccharide (LPS) O antigens and\/or secreted cholera toxins are responsible for the protective adaptive immunity, in conjunction with an effective mucosal immunologic memory that can elicit a rapid anamnestic SIgA antibody response upon re-exposure to the antigen\/pathogen even many years later. Oral cholera vaccines (OCVs), based on inactivated Vibrio cholerae whole-cell components, either together with the cholera toxin B subunit (Dukoral\u2122) or administered alone (Shanchol\u2122\/Euvichol-Plus\u2122) were shown to be consistently safe and effective in large field trials in all settings. These OCVs are recommended by the World Health Organisation (WHO) for the control of both endemic cholera and epidemic cholera outbreaks. OCVs are now a cornerstone in WHO\u2019s global strategy found in \u201cEnding Cholera: A Global Roadmap to 2030.\u201d However, the forecasted global demands for OCV, estimated by the Global Alliance for Vaccines and Immunization (GAVI) to 1.5 billion doses for the period 2020\u20132029, markedly exceed the existing manufacturing capacity. This calls for an increased production capacity of existing OCVs, as well as the rapid introduction of additional and improved vaccines under development.<\/jats:p>","DOI":"10.3390\/tropicalmed6020064","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T22:29:07Z","timestamp":1619648947000},"page":"64","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["An Update on Cholera Immunity and Current and Future Cholera Vaccines"],"prefix":"10.3390","volume":"6","author":[{"given":"Jan","family":"Holmgren","sequence":"first","affiliation":[{"name":"University of Gothenburg Vaccine Research Institute, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2051013614537819","article-title":"Killed oral cholera vaccines: History, development and implementation challenges","volume":"2","author":"Lopez","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_2","unstructured":"World Health Organisation (2017). Cholera vaccines: WHO position paper. Weekly Epidemiol. Rec., 92, 477\u2013500. Available online: http:\/\/www.who.int\/wer2."},{"key":"ref_3","unstructured":"World Health Organization\u2014Global Task Force on Cholera Control (2021, March 10). Ending cholera\u2014A roadmap for 2030. Available online: https:\/\/www.who.int\/cholera\/publications\/global-roadmap\/en\/."},{"key":"ref_4","unstructured":"Ouchterlony, \u00d6., and Holmgren, J. (1980). Cholera and Related Diarrheas: Molecular Aspects of a Global Health Problem 43rd Nobel Symposium 1978, S. Karger."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/292413a0","article-title":"Actions of cholera toxin and the prevention and treatment of cholera","volume":"292","author":"Holmgren","year":"1981","journal-title":"Nature"},{"key":"ref_6","first-page":"106","article-title":"Cholera and the immune response","volume":"33","author":"Holmgren","year":"1983","journal-title":"Prog. Allergy"},{"key":"ref_7","first-page":"945","article-title":"Cholera studies. IV. Problems in immunology","volume":"12","author":"Pollitzer","year":"1955","journal-title":"Bull. World Health Organ."},{"key":"ref_8","unstructured":"Kiyono, H., and Pascual, D.W. (2020). Cholera immunity and development and use of oral cholera vaccines for disease control. Mucosal Vaccines, Elsevier. [2nd ed.]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0035-9203(97)90523-X","article-title":"Gastric acid secretion and enteric infection in Bangladesh","volume":"91","author":"Evans","year":"1997","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/oxfordjournals.aje.a114050","article-title":"Predisposition for cholera of individuals with O blood group. Possible evolutionary significance","volume":"121","author":"Glass","year":"1985","journal-title":"Am. J. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/infdis\/159.4.770","article-title":"ABO blood groups and cholera: New observations on specificity of risk and modification of vaccine efficacy","volume":"159","author":"Clemens","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/gut.53.1.62","article-title":"Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut","volume":"53","author":"Qadri","year":"2004","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/IAI.01900-06","article-title":"Broad up-regulation of innate defense factors during acute cholera","volume":"75","author":"Flach","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.micinf.2011.06.014","article-title":"Antimicrobial peptides in the duodenum at the acute and convalescent stages in patients with diarrhea due to Vibrio cholerae O1 or enterotoxigenic Escherichia coli infection","volume":"13","author":"Shirin","year":"2011","journal-title":"Microbes Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fimmu.2019.00269","article-title":"Requirement for Cyclic AMP\/Protein Kinase A-Dependent Canonical NF\u03baB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT","volume":"10","author":"Terrinoni","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/infdis\/149.6.884","article-title":"Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine","volume":"149","author":"Svennerholm","year":"1984","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/iai.13.3.735-740.1976","article-title":"Synergistic protective effect in rabbits of immunization with V. cholerae lipopolysaccharide and toxin\/toxoid","volume":"13","author":"Svennerholm","year":"1976","journal-title":"Infect. Immun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbadis.2003.08.004","article-title":"Lipopolysaccharides of Vibrio cholerae. I. Physical and chemical characterization","volume":"1639","author":"Chatterjee","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/infdis\/jir416","article-title":"Natural cholera infection-derived immunity in an endemic setting","volume":"204","author":"Ali","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/143.6.818","article-title":"Duration of infection-derived immunity to cholera","volume":"143","author":"Levine","year":"1981","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/oxfordjournals.aje.a113498","article-title":"Endemic cholera in rural Bangladesh, 1966\u20131980","volume":"116","author":"Glass","year":"1982","journal-title":"Am. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1172\/JCI115270","article-title":"Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses, gamma-interferon production, and evokes local immunological memory","volume":"88","author":"Quiding","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.vaccine.2013.04.066","article-title":"Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: A tool for assessing immunological memory","volume":"31","author":"Leach","year":"2013","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-3083.1977.tb00376.x","article-title":"Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination","volume":"6","author":"Svennerholm","year":"1977","journal-title":"Scand. J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/269602a0","article-title":"Development of improved cholera vaccine based on subunit toxoid","volume":"269","author":"Holmgren","year":"1977","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0264-410X(92)90324-D","article-title":"An oral B subunit: Whole cell vaccine against cholera","volume":"10","author":"Holmgren","year":"1992","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0140-6736(17)30559-7","article-title":"Cholera","volume":"390","author":"Clemens","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1016\/j.vaccine.2019.12.011","article-title":"Current and future cholera vaccines","volume":"29","author":"Shaikh","year":"2020","journal-title":"Vaccine"},{"key":"ref_29","unstructured":"Plotkin, S.A., Offit, P.A., Orenstein, W.A., and Edwards, K.M. (2021). Cholera Vaccines. Plotkin\u00b4s Vaccines, Elsevier. [8th ed.]."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(86)91944-6","article-title":"Field trial of oral cholera vaccines in Bangladesh","volume":"328","author":"Clemens","year":"1986","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up","volume":"335","author":"Clemens","year":"1990","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(94)90755-2","article-title":"Protective efficacy of oral whole-cell\/recombinant-B-subunit cholera vaccine in Peruvian military recruits","volume":"344","author":"Sanchez","year":"1994","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/158.2.372","article-title":"Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial","volume":"158","author":"Clemens","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0140-6736(91)92590-X","article-title":"Prevention of travellers\u2019 diarrhoea by oral B-subunit\/whole-cell cholera vaccine","volume":"338","author":"Peltola","year":"1991","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1708-8305.1995.tb00615.x","article-title":"Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell\/Recombinant B Subunit (WC\/rBS) Oral Cholera Vaccine Against Travelers\u2019 Diarrhea","volume":"2","author":"Scerpella","year":"1995","journal-title":"J. Travel Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(09)61297-6","article-title":"Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: An interim analysis of a cluster-randomised, double-blind, placebo-controlled trial","volume":"374","author":"Sur","year":"2009","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","article-title":"5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trial","volume":"13","author":"Bhattacharya","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2018.09.026","article-title":"The Euvichol story\u2014Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships","volume":"36","author":"Odevall","year":"2018","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","article-title":"PaxVax CVD 103-HgR single-dose live oral cholera vaccine","volume":"16","author":"Levine","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/S0264-410X(00)00006-2","article-title":"Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area","volume":"18","author":"Richie","year":"2000","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0140-6736(05)66550-6","article-title":"Herd immunity conferred by killed oral cholera vaccines in Bangladesh: A reanalysis","volume":"366","author":"Ali","year":"2005","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ali, M., Debes, A.K., Luquero, F.J., Kim, D.R., Park, J.Y., Digilio, L., Manna, B., Kanungo, S., Dutta, S., and Sur, D. (2016). Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002120"},{"key":"ref_43","first-page":"2134","article-title":"Cholera cases cluster in time and space in Matlab, Bangladesh: Implications for targeted preventive interventions","volume":"45","author":"Debes","year":"2016","journal-title":"Int. J. Epidemiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/inthealth\/ihaa042","article-title":"Spatial clustering of cholera cases in the Kathmandu Valley: Implications for a ring vaccination strategy","volume":"13","author":"Roskosky","year":"2021","journal-title":"Int. Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fpubh.2019.00211","article-title":"Assessing Vaccine Herd Protection by Killed Whole-Cell Oral Cholera Vaccines Using Different Study Designs","volume":"7","author":"Ali","year":"2019","journal-title":"Front Public Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4269\/ajtmh.15-0700","article-title":"Bertil, C.; Joseph, P.; Deroncelay, A.; Mabou, M.; Wright, P.F.; Guillaume, F.D.; Pape, J.W. Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up","volume":"94","author":"Rouzier","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e1028","DOI":"10.1016\/S2214-109X(18)30284-5","article-title":"Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: An extended case-control study","volume":"6","author":"Franke","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nature10392","article-title":"Evidence for several waves of global transmission in the seventh cholera pandemic","volume":"477","author":"Mutreja","year":"2011","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1126\/science.aad5901","article-title":"Genomic history of the seventh pandemic of cholera in Africa","volume":"358","author":"Weill","year":"2017","journal-title":"Science"},{"key":"ref_50","unstructured":"GAVI (2021, March 10). Cholera Supply and Procurement Roadmap Update, December 2018. Available online: https:\/\/www.gavi.org\/sites\/default\/files\/document\/cholera-roadmap-public-summarypdf.pdf."},{"key":"ref_51","unstructured":"WHO Global Task Force for Cholera Control (2021, March 10). Cholera Roadmap Research Agenda. Available online: www.gtfcc.org."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Karlsson, S.L., Ax, E., Nygren, E., K\u00e4llg\u00e5rd, S., Blomquist, M., Ekman, A., Benktander, J., Holmgren, J., and Lebens, M. (2014). Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108521"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1016\/j.vaccine.2020.10.043","article-title":"Development of Hillchol\u00ae, a low-cost inactivated single strain Hikojima oral cholera vaccine","volume":"38","author":"Sharma","year":"2020","journal-title":"Vaccine"},{"key":"ref_54","unstructured":"Holmgren, J., and Lebens, M. (2019). Whole Cell Vaccines and Methods of Production Thereof. PCT\/EP\/083082 25 November 2019, WIPO."},{"key":"ref_55","unstructured":"Holmgren, J., Lebens, M., Nordqvist, S., Terrinoni, M., L\u00f6fstrand, M., Jeverstam, F., K\u00e4llg\u00e5rd, S., Tarun Sharma, T., Khalid Ali, K., and Gill, G. (2019, January 16\u201318). Hillchol-B\u2122: Low-cost, thermostable dry formulation Hikojima whole-cell\/B-subunit enterocoated capsule oral cholera vaccine. Proceedings of the Vaccines for Enteric Diseases, Lausanne, Switzerland."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/514025","article-title":"Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers","volume":"176","author":"Sack","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1086\/432074","article-title":"Peru-15 Study Group. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh","volume":"192","author":"Qadri","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/IAI.73.5.3018-3024.2005","article-title":"The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers","volume":"73","author":"Jidy","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1016\/j.vaccine.2009.08.042","article-title":"Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults","volume":"27","author":"Valera","year":"2009","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1016\/j.vaccine.2009.05.065","article-title":"Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response","volume":"27","author":"Mahalanabis","year":"2009","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1128\/IAI.71.10.5498-5504.2003","article-title":"Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108","volume":"71","author":"Liang","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eaap8423","DOI":"10.1126\/scitranslmed.aap8423","article-title":"A live vaccine rapidly protects against cholera in an infant rabbit model","volume":"10","author":"Hubbard","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sit, B., Zhang, T., Fakoya, B., Akter, A., Biswas, R., Ryan, E.T., and Waldor, M.K. (2019). Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice. PLoS Negl. Trop. Dis., 13.","DOI":"10.1101\/554303"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/infdis\/168.5.1169","article-title":"Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children","volume":"168","author":"Simanjuntak","year":"1993","journal-title":"J. Infect. Dis."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/6\/2\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:54:47Z","timestamp":1760162087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/6\/2\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["tropicalmed6020064"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed6020064","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]}}}